Mayo Clinic Laboratories > Neurology > Alzheimer’s disease

Alzheimer’s disease

Accurate answers to guide care

The swift pace of research and discovery around Alzheimer’s disease has yielded new treatments that, more than ever before, give patients a reason to hope. Early, accurate diagnosis is important to access FDA-approved medications and improve patient care.

Our innovative Alzheimer's disease evaluations use cerebrospinal fluid (CSF) biomarkers to achieve a high concordance with amyloid positron emission tomography (PET) scans. Optimized to reduce pre-clinical variability and ensure diagnostic accuracy, these clinically validated tests deliver fast, accurate answers that can improve access to Alzheimer’s disease treatments.

Alzheimer’s disease Test menu

Alzheimer’s disease

Diagnosing Alzheimer’s disease is a challenge. We use the most up-to-date methodology: automated immunoassays with innovative instrumentation. Our results are based on ratios of p-tau and AB42 (Mayo ID: ADEVL) and AB42 and AB40 (Mayo ID: AMYR), which allow for greater than 90% diagnostic accuracy compared to standard assessments. We also use low-binding tubes, resulting in fewer falsely abnormal results for patients.

Key testing

Advantages

  • Uses the most up-to-date methodology (automated immunoassay).
  • Evaluates multiple biomarkers and ratios.
  • Aligns with consensus research diagnostic criteria for Alzheimer’s disease, mild cognitive impairment (MCI), and pre-clinical Alzheimer’s disease as proposed by the National Institute on Aging and Alzheimer’s Associate Research Framework.2
  • AMYR is an FDA-approved evaluation.
  • Positive result enables access to FDA-approved medications.

When to consider testing

  • For the differential diagnosis of Alzheimer’s disease versus other causes of cognitive impairment.
  • When patients present with atypical dementia symptoms.
  • To assess Alzheimer’s disease pathology in a mixed diagnosis.
  • To allow for eligibility into clinical trials.

More information

Clear results that guide treatment decisions

A diagnosis of Alzheimer’s disease can change patients' lives. Receiving a fast, definitive answer from a healthcare institution they trust can provide hope and a plan for their future. Whether it is the right treatment for symptom management, confirmation of diagnosis, or eligibility for clinical trials, we are here to provide the highest quality of care. 

Fast, cost-effective answers when you need them the most

A differential diagnosis can change treatment and improve patient care. With our testing, a patient receives the answers they need in as little as one day. They don’t have to wait weeks or months to be placed on the right treatment and start planning for their future.

A complementary solution to assist with diagnosis

Standard assessment of suspected Alzheimer's disease patients through clinical and cognitive assessment is 70%–80% accurate. By adding our Alzheimer's disease evaluations, physicians can increase diagnostic accuracy by 12%–22% to ensure they are providing the correct diagnosis and treatment for patients.

Confirm neuronal damage

For patients suspected of having Alzheimer’s disease, testing for neurofilament light chain (NfL), a generic marker of neurodegeneration, can confirm a neurodegenerative disease process. Mayo Clinic Laboratories has developed an innovative assay to test for elevated levels of NfL in the blood. Positive test results not only confirm neuronal damage but can offer insights on disease progression and prognosis to guide therapeutic decision-making.

Highlights


References
  1. Alzheimer’s Disease Facts and Figures. Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures. Published 2023. Accessed Sept. 15, 2023.
  2. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi:10.1016/j.jalz.2018.02.018. PMID: 29653606; PMCID: PMC5958625.
  3. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019 Apr 2;321(13):1286-1294.
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.